Chapter 4 Immunoassays for therapeutic drug monitoring and clinical toxicology

Handbook of Analytical Separations

Volumn 5, Issue , 2004, Pages 95-112

  Clarke, William ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649397531     PISSN: 15677192     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7192(04)80005-6     Document Type: Chapter

References (54)

1. Barrett C., Good C., and Moore C. Comparison of point-of-collection screening of drugs of abuse in oral fluid with a laboratory-based urine screen. Forensic Sci. Int. 122 (2001) 163-166
2. Huestis M.A., Cone E.J., Wong C.J., Umbricht A., and Preston K.L. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J. Anal. Toxicol. 24 (2000)
3. Chronister C.W., Waltrath J.C., and Goldberger B.A. Rapid detection of benzoylecgonine in vitreous humor by enzyme immunoassay. J. Anal. Toxicol. 25 (2001) 621-624
4. In: Chan D.W. (Ed). Immunoassay automation: A practical guide (1992), Academic Press, San Diego
5. In: Chan D.W. (Ed). Immunoassay automation: An updated guide to systems (1996), Academic Press, San Diego
6. In: Chan D.W. (Ed). Immunoassay: A practical guide (1987), Academic Press, San Diego
7. Ekins R. Toward immunoassays of greater sensitivity, specificity and speed: an overview. In: Albertini A., and Ekins R. (Eds). Monoclonal antibodies and developments in immunoassay (1981), Elsevier/ North-Holland Biomedical Press, New York 3-21
8. Inbar S., Grenner G., Blackwood J., Long E., Bowen M., and Meneghini F. Dry chemistry thin film immunoassay. Ann. Biol. Clin. 48 (1990) 385-390
9. O'Connell M.T., Ratnaraj N., Elyas A.A., Doheny M.H., Darsot S., and Patsalos P.N. A comparison of the OPUS and TDx analysers for antiepileptic drug monitoring. Ther. Drug Monit. 17 (1995) 549-555
10. Picardo M., and Hughes K.T. Scintillation proximity assays. In: Devlin J.P. (Ed). High throughput screening (1997), Marcel Dekker, New York 307-316
11. Castro A., and Mittleman R. Determination of drugs of abuse in body fluids by radioimmunoassay. Clin. Biochem. 11 (1978) 103-105
12. DeRemer M., D'Ambrosio R., Bartos L., Cousins S., and Morse G.D. Radioimmunoassay of zidovudine: extended use and potential application. Ther. Drug Monit. 19 (1997) 195-200
13. Tschop M., Bere H.M., Nieschlag E., Dressendorfer R.A., and Strasburger C.J. A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosteronereplacement therapy with testosterone buciclate. Clin. Chem. Lab. Med. 36 (1998) 223-230
14. Tuomola M., Cooper K.M., Lahdenpera S., Baxter G.A., Elliott C.T., Kennedy D.G., and Lovgren T. A specificity-enhanced time-resolved fluoroimmunoassay for zeranol employing the dry reagent all-in-one-well principle. Analyst 127 (2002) 83-86
15. Zaninotto M., Secchiero S., Paleari S.C., and Burlina A. Performance of a fluorescence polarization immunoassay system evaluated by therapeutic monitoring of four drugs. Ther. Drug Monit. 14 (1992) 301-305
16. Wong S.H.Y. Therapeutic drug monitoring for immunosuppressants. Clin. Chim. Acta. 313 (2001) 241-253
17. Hanseler E., and Keller H. Sensitivity and specificity of cocaine metabolite screening in view of the analytical performance of a fluorescence polarisation immunoassay. Eur. J. Clin. Chem. Clin. Biochem. 32 (1994) 865-871
18. Armbruster D.A., Schwarzhoff R.H., Hubster E.C., and Liserio M.K. Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clin. Chem. 39 (1993) 2137-2146
19. Ullman E., and Khanna P. Fluorescence excitation transfer immunoassays. In: Colwick S.P., and Kaplan N.O. (Eds). Methods in enzymology Vol. 74 (1981), Academic Press, New York 28-60
20. Anderson F.P., and Miller W.G. Fiber optic immunochemical sensor for continuous, reversible measurement of phenytoin. Clin. Chem. 34 (1988) 1417-1421
21. Plebani M., and Burlina A. Fluorescence energy transfer immunoassay of digoxin in serum. Clin. Chem. 31 (1985) 1879-1881
22. Porstmann T., and Kiessig S.T. Enzyme immunoassay techniques: an overview. J. Immunol. Methods 150 (1992) 5-21
23. Matalka K., El-Thaher T., Saleem M., Arafat T., Jehanli A., and Badwan A. Enzyme linked immunosorbent assay for determination of amlodipine in plasma. J. Clin. Lab. Anal. 15 (2001) 47-53
24. Ownby C.L., Reisbeck S.L., and Allen R. Levels of therapeutic antivenin and venom in a human snakebite victim. South Med. J. 89 (1996) 803-806
25. Jenkins S.H. Homogeneous enzyme immunoassay. J. Immunol. Methods 150 (1992) 91-97
26. Higgins T.N. Enzyme immunoassay of valproic acid using the Abbott ABA-200 analyzer. Clin. Biochem. 16 (1983) 222-223
27. Miller E., Walberg C., and Haywood L.J. Rapid assessment of lidocaine in cardiac patients by enzyme immunoassay. Ther. Drug Monit. 3 (1981) 85-89
28. Weber L.T., Shipkova M., Armstrong V.W., Wagner N., Schutz E., Mehls O., Zimmerhackl L.B., Oellerich M., and Tonshoff B. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid inpediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin. Chem. 48 (2002) 517-525
29. Roberts W.L., Annesley T.M., De B.K., Moulton L., Juenke J.M., and Moyer T.P. Performance characteristics of four free phenytoin immunoassays. Ther. Drug Monit. 23 (2001) 148-154
30. Kunsman G.W., Manno J.E., Cockerham K.R., and Manno B.R. Application of the Syva EMIT and Abbott TDx amphetamine immunoassays to the detection of 3,4-methylene-dioxymethamphetamine(MDMA) and 3,4-methylene-dioxyethamphetamine (MDEA) in urine. J. Anal. Toxicol. 14 (1990) 149-153
31. Charlier C.J., and Plomteux G.J. Evaluation of Emit® Tox benzodiazepine and barbiturate assays on the Vitalab Viva analyzer and FPIA on the Abbott Adx analyzer. Clin. Chem. Lab. Med. 38 (2000) 615-618
32. Engel W.D., and Khanna P.L. CEDIA® in vitro diagnostics with a novel homogeneous immunoassay technique: current status and future prospects. J. Immunol. Methods 150 (1992) 99-102
33. Schutz E., Svinarov D., Shipkova M., Niedmann P.-D., Armstrong V.W., Wieland E., and Oellerich ?. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin. Chem. 44 (1998) 2158-2164
34. G K., W C., A C., O D., I D., E H., et al. Results of the multicenter evaluation of the CEDIA® phenobarbital assay. Wein Klin Wochenschr Suppl 191 (1992) 41-47
35. Engel W.D., and Khanna P.L. CEDIA in vitro diagnostics with a novel homogeneous immunoassay technique. Current status and future prospects. J. Immunol. Methods 150 (1992) 99-102
36. Meatherall R.C., and Fraser A.D. CEDIA dau benzodiazepine screening assay: a reformulation. J. Anal. Toxicol. 22 (1998) 270-273
37. Armbruster D.A., Hubster E.C., Kaufman M.S., and Ramon M.K. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening. Clin. Chem. 41 (1995) 92-98
38. Seto Y., Iba T., and Abe K. Development of ultra-high sensitivity bioluminescent enzyme immunoassay for prostate-specific antigen (PSA) using firefly luciferase. Luminescence 16 (2001) 285-290
39. Siddiqi A.M., Jennings V.M., Kidd M.R., Actor J.K., and Hunter R.L. Evaluation of electro-chemiluminescence-and bioluminescence-based assays for quantitating specific DNA. J. Clin. Lab. Anal. 10 (1996) 423-431
40. Kricka L.J. Chemiluminescent and bioluminescent techniques. Clin. Chem. 37 (1991) 1472-1481
41. Frank E.L., Schwarz E.L., Juenke J., Annesley T.M., and Roberts W.L. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am. J. Clin. Pathol. 18 (2002) 124-131
42. Grimshaw C., Gleason C., Chojnicki E., and Young J. Development of an equilibrium immunoassay using electrochemiluminescent detection for a novel recombinantprotein product and its application to pre-clinical product development. J. Pharm. Biomed. Analysis 16 (1997) 605-612
43. Bronstein I., Edwards B., and Voyta J.C. 1,2-dioxetanes: novel chemiluminescent enzyme substrates. Applications to immunoassays. J. Biolumin. Chemilumin 4 (1989) 99-111
44. Janda I., Jaensch H., Braun J., and Wood W.G. A comparison of four immunometric assays for myeloperoxidase using luminescent and colorimetric signal detection. J. Clin. Chem. Clin. Biochem 28 (1990) 475-480
45. Klee G.G. Human anti-mouse antibodies. Arch. Pathol. Lab. Med. 124 (2000) 921-923
46. Miles L.E. Properties, variants, and applications of the immunoradiometric assay method. Ric. Clin. Lab. 5 (1975) 59-72
47. Wu J.T., and Christensen S.E. Effect of different test designs of immunoassays on "Hook Effect" of CA 19-9 measurement. J. Clin. Lab. Analysis 5 (1991) 228-232
48. Apple F.S. Clinical and analytical standardization issues confronting cardiac troponin I. Clin. Chem. 45 (1999) 18-20
49. Wu A.H., Feng YJ., Moore R., Apple F.S., McPherson PH., Buechler K.F., et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assaysfor troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. Clin. Chem. 44 (1998) 1198-1208
50. Somerville A.L., Wright D.H., and Rotschafer J.C. Implications of Vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19 (1999) 702-707
51. Wu S.L., Li W., Wells A., and Dasgupta A. Digoxin-like and digitoxin-like immunoreactive substances in elderly people. Am. J. Clin. Pathol. 115 (2001) 600-604
52. Steimer W., Muller C., Eber B., and Emmanuilidis K. Intoxication due to negative canrenone interference in digoxin drug monitoring. Lancet 354 (1999) 1176-1177
53. Peace M.R., Tarnai L.D., and Poklis A. Performance evaluation of four on-site drug-testing devices for detection of drugs of abuse in urine. J. Anal. Toxicol. 24 (2000) 589-594
54. In: Price C.P., and Newman D.J. (Eds). Principles and practice of immunoassay. 2nd ed. (1997), Stockton Press, New York